168 related articles for article (PubMed ID: 34196599)
1. The role of
Brunette CA; Vassy JL
Pharmacogenomics; 2021 Jul; 22(11):649-656. PubMed ID: 34196599
[No Abstract] [Full Text] [Related]
2. Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.
Peyser B; Perry EP; Singh K; Gill RD; Mehan MR; Haga SB; Musty MD; Milazzo NA; Savard D; Li YJ; Trujilio G; Voora D
Circ Genom Precis Med; 2018 Sep; 11(9):e002228. PubMed ID: 30354330
[TBL] [Abstract][Full Text] [Related]
3. Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review.
Vassy JL; Chun S; Advani S; Ludin SA; Smith JG; Alligood EC
Clin Pharmacol Ther; 2019 Aug; 106(2):360-373. PubMed ID: 30137643
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics and statin-related myopathy: what do we know?
Turner RM; Radman I; Bozina N; Alfirevic A
Pharmacogenomics; 2020 Aug; 21(12):821-825. PubMed ID: 32723135
[No Abstract] [Full Text] [Related]
5. Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial.
Vassy JL; Gaziano JM; Green RC; Ferguson RE; Advani S; Miller SJ; Chun S; Hage AK; Seo SJ; Majahalme N; MacMullen L; Zimolzak AJ; Brunette CA
JAMA Netw Open; 2020 Dec; 3(12):e2027092. PubMed ID: 33270123
[TBL] [Abstract][Full Text] [Related]
6. Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.
Ahangari N; Doosti M; Ghayour Mobarhan M; Sahebkar A; Ferns GA; Pasdar A
Ann Med; 2020 Dec; 52(8):462-470. PubMed ID: 32735150
[TBL] [Abstract][Full Text] [Related]
7. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
Ramakumari N; Indumathi B; Katkam SK; Kutala VK
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243
[TBL] [Abstract][Full Text] [Related]
8. The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care.
Vassy JL; Brunette CA; Majahalme N; Advani S; MacMullen L; Hau C; Zimolzak AJ; Miller SJ
Contemp Clin Trials; 2018 Dec; 75():40-50. PubMed ID: 30367991
[TBL] [Abstract][Full Text] [Related]
9. A cost effective RFLP method to genotype Solute carrier organic anion 1B1 (SLCO1B1) c.1929A>C (p.Leu643Phe, rs34671512); a variant with potential effect on rosuvastatin pharmacokinetics.
Soko ND; Masimirembwa C; Dandara C
BMC Res Notes; 2018 Jun; 11(1):384. PubMed ID: 29898760
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
Cooper-DeHoff RM; Niemi M; Ramsey LB; Luzum JA; Tarkiainen EK; Straka RJ; Gong L; Tuteja S; Wilke RA; Wadelius M; Larson EA; Roden DM; Klein TE; Yee SW; Krauss RM; Turner RM; Palaniappan L; Gaedigk A; Giacomini KM; Caudle KE; Voora D
Clin Pharmacol Ther; 2022 May; 111(5):1007-1021. PubMed ID: 35152405
[TBL] [Abstract][Full Text] [Related]
11. A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance.
Bigossi M; Maroteau C; Dawed AY; Taylor A; Srinivasan S; Melhem AL; Pearson ER; Pola R; Palmer CNA; Siddiqui MK
Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):536-545. PubMed ID: 37253618
[TBL] [Abstract][Full Text] [Related]
12. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms.
Linskey DW; English JD; Perry DA; Ochs-Balcom HM; Ma C; Isackson PJ; Vladutiu GD; Luzum JA
Pharmacogenet Genomics; 2020 Dec; 30(9):208-211. PubMed ID: 32453264
[TBL] [Abstract][Full Text] [Related]
13.
Massmann A; Van Heukelom J; Green RC; Hajek C; Hickingbotham MR; Larson EA; Lu CY; Wu AC; Zoltick ES; Christensen KD; Schultz A
Pharmacogenomics; 2023 May; 24(7):399-409. PubMed ID: 37232094
[No Abstract] [Full Text] [Related]
14. Atorvastatin-associated rhabdomyolysis in a patient with a novel variant of the SLCO1B1 gene: A case report.
Kiage J; Venkatanarayan A; Roth M; Elam M
J Clin Lipidol; 2022; 16(1):23-27. PubMed ID: 34887219
[TBL] [Abstract][Full Text] [Related]
15. Statin-induced rhabdomyolysis from azithromycin interaction in a patient with heterozygous SLCO1B1 polymorphism.
Burns H; Russell L; Cox ZL
J Clin Pharm Ther; 2021 Jun; 46(3):853-855. PubMed ID: 33277702
[TBL] [Abstract][Full Text] [Related]
16. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis.
Xiang Q; Chen SQ; Ma LY; Hu K; Zhang Z; Mu GY; Xie QF; Zhang XD; Cui YM
Pharmacogenomics J; 2018 Dec; 18(6):721-729. PubMed ID: 30250148
[TBL] [Abstract][Full Text] [Related]
17. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Ramsey LB; Johnson SG; Caudle KE; Haidar CE; Voora D; Wilke RA; Maxwell WD; McLeod HL; Krauss RM; Roden DM; Feng Q; Cooper-DeHoff RM; Gong L; Klein TE; Wadelius M; Niemi M
Clin Pharmacol Ther; 2014 Oct; 96(4):423-8. PubMed ID: 24918167
[TBL] [Abstract][Full Text] [Related]
18. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
[TBL] [Abstract][Full Text] [Related]
19. Effect of SLCO1B1 gene polymorphisms and vitamin D on statin-induced myopathy.
Alghalyini B; El Shamieh S; Salami A; Visvikis Siest S; Fakhoury HM; Fakhoury R
Drug Metab Pers Ther; 2018 Mar; 33(1):41-47. PubMed ID: 29420305
[TBL] [Abstract][Full Text] [Related]
20. Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.
Licito A; Marotta G; Battaglia M; Benincasa G; Mentone L; Grillo MR; De Lucia V; Leonardi G; Bignucolo A; Comello F; Di Francia R; De Lucia D
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):469-477. PubMed ID: 31957862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
